Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Nov 15, 2020 1:11pm
234 Views
Post# 31903261

RE:RE:RE:Barbados Contract Yields ~$12 Million In Revenue Alone!

RE:RE:RE:Barbados Contract Yields ~$12 Million In Revenue Alone!

So assume an average of $250 a test and say 50 people per flight which is well under 50% capacity. That's $12,500 per flight.  800 flights a year is $10 million.  


So I can see $6-12 million as being realistic. Not to mention the PR and potential for other countries to follow suit.


frewil11 wrote: Yes there's probably very little flights if any , but this type of testing could go on for at least 2 to 3 more years, it might turn out to be the new norm for many more than that, so any contracts with travel is huge if you ask me.

 

<< Previous
Bullboard Posts
Next >>